Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
Blood Cancer Journal|February 4, 2017
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromesR T Swords, J Watts, H P Erba, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Blood Cancer Journal|February 4, 2017
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromesR T Swords, J Watts, H P Erba, et al.
Haematologica|August 3, 2023
Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemiaLaura W Dillon, Jake Higgins, Hassan Nasif, et al.
Blood Neoplasia|September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AMLVinod A Pullarkat, Mark Levis, James McCloskey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsHagop M Kantarjian, Harry P Erba, David Claxton, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Acute Myelogenous LeukemiaF R Appelbaum, M R Baer, M H Carabasi, et al.
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Pageof 17